Table.
Patient characteristics | Risk score |
---|---|
High risk (lung, lymphoma, gynecologic, bladder, testicular) | 1 |
Pre-chemotherapy platelet count ≥ 350×109/L | 1 |
Hemoglobin level < 10 mg/mL or use of red cell growth factors | 1 |
Pre-chemotherapy leukocyte count > 11 ×109/L | 1 |
BMI ≥ 35 kg/m2 | 1 |
The AVERT study used a modified Khorana to include patients with brain tumor as very high risk cancer (risk score of 2) and myeloma and kidney cancer as high risk cancer (risk score of 1).